Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-Center, Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma (HCC)

NCT01078415 is registered in ClinicalTrials.gov with Angiodynamics, Inc. as lead sponsor.

NCT NCT01078415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01078415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-Center, Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma (HCC)
Lead sponsor
Angiodynamics, Inc.
Phase
Not applicable
Overall status
Completed
Start date
February 28, 2010
Completion date
June 30, 2013
Enrollment
26 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular